Latest 10-K annual reports

Marblegate Capital Corporation reported a net loss of $44.1 million for 2025, driven by a significant deferred tax liability, despite strong fleet operations growth and strategic financing initiatives.

Guerrilla RF, Inc. announced a 13% revenue increase to $22.7 million in fiscal year 2025, driven by automotive and catalog market growth, alongside a significant reduction in net operating losses.

Cognition Therapeutics, a clinical-stage biopharmaceutical company, reported its 2025 annual results, highlighting progress in its zervimesine clinical programs for Alzheimer's and Lewy body dementia, while facing continued net losses and capital needs.

Celcuity Inc. announced the FDA's acceptance of its New Drug Application for gedatolisib with Priority Review, targeting HR+/HER2advanced breast cancer, following strong Phase 3 clinical trial results.

MapLight Therapeutics reported a significant net loss in 2025 while progressing its lead CNS drug candidates, ML-007C-MA and ML-004, through Phase 2 clinical trials with key data expected in 2026 and 2027.

Rockwell Medical reports a significant net sales decrease in 2025, primarily due to reduced DaVita purchases, while extending its product purchase agreement with DaVita through 2026 and focusing on new customer growth.

WhiteFiber, Inc. reported a net loss of $24.7 million for the fiscal year ended December 31, 2025, despite significant revenue growth in cloud and colocation services and substantial investments in AI infrastructure.

K2 Capital Acquisition Corporation's 2025 10-K outlines its blank check company structure, successful IPO, and strategic focus on Physical AI, SMRs, and European technology for its initial business combination.

22nd Century Group reported significant losses and negative cash flow for 2025, raising substantial doubt about its ability to continue as a going concern, despite strategic advancements in its reduced nicotine content tobacco products and a recent capital raise.

M-tron Industries reports strong 2025 financial results with significant revenue and net income growth, driven by defense programs and strategic investments, while enhancing cybersecurity measures.

United Security Bancshares reported a decrease in net income for 2025 to $12.3 million, down from $14.8 million in 2024, while announcing an all-stock merger with Community West Bancshares expected to close in Q2 2026.

Vanjia Corporation filed its 2025 annual report, revealing a net loss and outlining plans to build affordable homes in Houston, supported by a $5 million line of credit from its officer.

Health In Tech, Inc. announced robust financial performance for fiscal year 2025, driven by significant revenue growth and expanded platform adoption, despite pausing HI Card development.

Tron Inc. reports a substantial net loss for 2025 driven by digital asset revaluations and an intangible asset impairment, while strategically pivoting to a TRON blockchain-integrated treasury and toy business.

Atossa Therapeutics reports progress in its (Z)-endoxifen clinical trials for breast cancer and rare diseases, alongside continued operating losses and a recent reverse stock split.

Lionheart Holdings, a blank check company, reported net income for fiscal year 2025 but faces substantial doubt about its ability to continue as a going concern if it fails to complete a business combination by June 20, 2026.

Axiom Intelligence Acquisition Corp 1's annual report outlines its blank check company structure, IPO details, and strategic focus on European infrastructure for its initial business combination.

Immix Biopharma reports positive interim Phase 2 data for its lead CAR-T candidate NXC-201 in AL Amyloidosis, alongside significant capital raises and key regulatory designations.

Finward Bancorp's 2025 net income declined significantly from 2024 due to a prior year's one-time gain, while core banking metrics like net interest income and asset quality showed improvement.

Stardust Power Inc. reports significant net losses and a going concern warning, despite progress in its Oklahoma lithium refinery project and securing non-binding supply and offtake agreements.

Central Bancompany, Inc. announced significant financial growth in its 2025 annual report, driven by increased net interest income and wealth management assets, following its successful November 2025 IPO.

DT Cloud Star Acquisition Corporation announced a definitive business combination agreement with PrimeGen US, Inc., despite an auditor's going concern warning and significant share redemptions.

Keen Vision Acquisition Corporation reports a significant reduction in its trust account balance due to redemptions and a going concern warning, while pursuing a new, smaller business combination target.

ServiceTitan, Inc. announced a 24% increase in total revenue to $961.0 million for fiscal 2026, while reporting a net loss of $159.9 million as it invests in platform expansion and AI.

EWSB Bancorp, Inc. reported a significant increase in its net loss to $4.1 million for the fiscal year ended December 31, 2025, alongside non-compliance with state and internal capital requirements.

Park Dental Partners, Inc. reported a 6.4% increase in total revenues to $244.5 million for 2025, driven by acquisitions and same practice revenue growth, despite a net loss of $0.358 million.

Lucid Diagnostics' 2025 annual report details revenue growth, significant capital raises, and key product advancements, alongside persistent operating losses and substantial doubt about its ability to continue as a going concern.

Precigen achieved a significant milestone with full FDA approval for Papzimeos, its first commercial product for recurrent respiratory papillomatosis, as it navigates substantial financial losses and strategic pipeline adjustments.

SeaStar Medical Holding Corporation's latest 10-K filing reveals increased revenue from its pediatric SCD therapy but highlights substantial doubt about its ability to continue as a going concern due to ongoing losses and capital needs.

Marpai Inc. reported a significant revenue decline and ongoing operating losses for 2025, leading to substantial doubt about its ability to continue as a going concern, despite strategic restructuring efforts.